Cargando…

Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey

INTRODUCTION: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Ziver, Bıcakcıgil, Muge, Aksu, Kenan, Kamali, Sevil, Akar, Servet, Onen, Fatos, Karadag, Omer, Ozbalkan, Zeynep, Ates, Askin, Ozer, Huseyin TE, Yilmaz, Vuslat, Seyahi, Emire, Ozturk, Mehmet A, Cefle, Ayse, Cobankara, Veli, Onat, A Mesut, Tunc, Ercan, Düzgün, Nursen, Aydin, Sibel Z, Yilmaz, Neslihan, Fresko, İzzet, Karaaslan, Yasar, Kiraz, Sedat, Akkoc, Nurullah, Inanc, Murat, Keser, Gokhan, Uyar, F Aytul, Direskeneli, Haner, Saruhan-Direskeneli, Güher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392822/
https://www.ncbi.nlm.nih.gov/pubmed/22309845
http://dx.doi.org/10.1186/ar3730
Descripción
Sumario:INTRODUCTION: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. METHODS: TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. RESULTS: We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). CONCLUSIONS: In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further.